Climb Bio, Inc.

Climb Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell up to $100 million of its common stock through an "at the market offering." This new agreement replaces a previous Equity Distribution Agreement with Oppenheimer & Co. Inc. for up to $22.35 million, which was terminated effective June 11, 2026, with no shares sold under it. The new offering provides the company with capital-raising flexibility.

Climb Bio, Inc. announced positive initial data from the Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP). The drug was generally well tolerated at 250 mg and 500 mg doses, with no serious adverse events or treatment discontinuations. Efficacy data from the 250 mg cohort showed significant B-cell depletion and increased platelet counts, with durable responses in a majority of patients, including those previously treated with rituximab.

Climb Bio, Inc. stockholders approved an amendment to the 2021 Equity Incentive Plan at the 2026 Annual Meeting, which now includes prefunded warrants in the calculation of the annual share pool increase. Additionally, Alexander (Bo) Cumbo and Douglas Williams, Ph.D., were elected to the Board of Directors for three-year terms. Stockholders also ratified PricewaterhouseCoopers LLP as the independent auditor for 2026 but did not approve an amendment to the Certificate of Incorporation regarding director removal for "cause".

Climb Bio, Inc. announced positive translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. A model derived from non-human primate data projected dose-dependent IgA suppression, suggesting potential for less-frequent dosing. Preliminary safety data from 49 healthy volunteers showed CLYM116 was generally well tolerated with no serious adverse events. The company plans to advance CLYM116 into further clinical development, and its partner Mabworks expects to initiate Phase 2 dosing in IgAN patients in Q3 2026.

Climb Bio, Inc. announced favorable initial Phase 1 safety data for its anti-APRIL monoclonal antibody, CLYM116, supporting its continued development for IgA nephropathy (IgAN). The data, presented at the ERA Congress 2026, showed CLYM116 was generally well tolerated with no unexpected safety findings in healthy volunteers. The company's partner, Mabworks, expects to initiate dosing in IgAN patients for a Phase 2 study in Q3 2026, and Climb Bio plans to share further data in late summer.

Climb Bio, Inc. reported a net loss of $13.7 million for the first quarter of 2026, an improvement from the $20.8 million net loss in the same period last year, with net loss per share improving to $(0.20). Research and development expenses significantly decreased, contributing to the narrower loss. However, cash and cash equivalents declined substantially, though total liquidity including marketable securities is expected to cover operating requirements for at least the next twelve months. The company also disclosed ongoing legal proceedings and identified material weaknesses in its internal control over financial reporting.

Climb Bio, Inc. reported its first quarter 2026 financial results and provided business updates. The company secured a $110 million private placement financing, significantly strengthening its balance sheet. For Q1 2026, R&D expenses were $9.4 million, down from $17.3 million in Q1 2025, while G&A expenses were $5.8 million. Climb Bio also provided updates on its budoprutug and CLYM116 programs, including robust B-cell depletion observed with budoprutug's subcutaneous formulation and anticipated data readouts for ongoing clinical trials in 2026.

Climb Bio, Inc. announced positive topline data for its budoprutug subcutaneous formulation, demonstrating robust B-cell depletion and good tolerability in healthy volunteers. The company's clinical trials for budoprutug in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE) are enrolling as planned. Initial data from the ITP trial is expected in June 2026, with pMN and SLE data anticipated in Q4 2026. Budoprutug also received Fast Track Designation for pMN.

Climb Bio, Inc. announced it has entered into a securities purchase agreement for a private placement, expecting to raise approximately $110.0 million in gross proceeds. The offering includes the sale of 9,481,000 shares of common stock at $9.50 per share and 2,106,000 pre-funded warrants at $9.4999 per warrant, with an exercise price of $0.0001 per share. The private placement saw participation from new and existing institutional accredited investors, including Adage Capital Partners, L.P. and RA Capital Management, and is expected to close around April 29, 2026.

Climb Bio, Inc. (CLYM) announced a private placement to raise approximately $110.0 million in gross proceeds. The company is selling 9,481,000 shares of common stock at $9.50 per share and 2,106,000 pre-funded warrants at $9.4999 per warrant. The placement, expected to close around April 29, 2026, saw participation from new and existing institutional investors including Adage Capital Partners, RA Capital Management, and Redmile.